Abstract:The avoidance of immune surveillance by malignant plasma cells (PCs) in multiple myeloma (MM) is mediated by different mechanisms, among which an induction of T cell exhaustion and expansion of myeloid-derived suppressor cells (MDSCs) appear to play substantial roles, but it is still a lack of data on possible MDSC-mediated induction of T cell exhaustion. The aim of the present work was to evaluate possible relationship between frequencies of MM PCs, MDSCs and phenotypically exhausted PD-1 + and TIM-3 + T cells in bone marrow (BM) samples and peripheral blood (PB) of MM patients at various disease stages. Peripheral blood (n = 88) and BM samples (n = 56) were obtained from MM patients (newly diagnosed (n = 6), patients in remission (n = 71) and with progressive disease (n = 11)). Frequencies of T cells expressing checkpoint receptors PD-1 and TIM-3, polymorphonuclear MDSCs (PMN-MDSCs, Lin - CD14 - HLA-DR - CD33 + CD15 + /CD66b + ), monocyte MDSCs (M-MDSCs, CD14 + HLA-DR low/- ), early MDSCs (E-MDSCs, Lin - HLA-DR - CD33 + CD15 - /CD66b - ), and MM PCs (CD45 dim CD38 + CD138 + CD56 + CD19 - CD117 + CD27 - CD81 - ) were assessed with flow cytometry. Circulating and BM-resident PD-1 + /TIM-3 + T cell subsets, BM E-MDSCs, as soon as MM PCs and serum beta2-microglobulin (B2-M) levels were gradually increased in patients at different stages. Despite that, there were no associations between the markers of tumor load and the studied cell subsets. In patients in remission, BM PMN-MDSCs negatively correlated with CD4 + T cells, CD4 + PD-1 + and CD8 + TIM-3 + T cell subsets; there were positive correlations between BM E-MDSCs and CD4 + PD-1 + TIM-3 + cells and PB M-MDSCs and CD8 + PD-1 + and (as a trend) CD8 + TIM-3 + T cells. We found no associations for the samples of patients at diagnosis and with progression. We can conclude that a possible mutual influence of malignant PCs, MDSCs and PD-1 + /TIM-3 + T cells is nonlinear, especially during a manifest tumor growth at diagnosis and progression. The detected negative correlations between resident PMN- MDSCs and T cell subsets might be associated with MDSC suppressive function, affecting both predominantly activated PD-1 + cells and exhausted TIM-3 + subsets. The positive correlations between BM E-MDSCs and CD4+PD-1 + TIM-3 + cell subset and circulating M-MDSCs and PD-1 + and TIM-3 + CD8 + T cells might confirm an ability of MDSCs to induce T cell exhaustion.

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Mechanisms of resistance to daratumumab in patients with multiple myeloma

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma

High-Dimensional Spectral Analysis of Natural Killer Cell Alterations Identifies a Subgroup with an Enhanced Daratumumab Treatment Response in Relapsed and Refractory Multiple Myeloma

Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients

Hallmarks of tumor-experienced T cells are absent in multiple myeloma patients from diagnosis through maintenance therapy

Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Attempt to assess direct interactions between tumor burden, myeloid-derived suppressor cells and PD-1- and TIM-3-expressing T cells in multiple myeloma patients

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

[Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma]

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

Targeting NKG2D/NKG2DL Axis In Multiple Myeloma Therapy

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Lymphocyte profile in peripheral blood of patients with multiple myeloma

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma